Lupin receives USFDA approval of Goa plant

Lupin Ltd has cleared inspection of USFDA without any critical observation of Goa manufacturing plant during an inspection in March 2016.
The development comes as a major relief to the company, India’s third largest pharmaceutical firm, as its Goa unit accounts for about 30-40% of its sales in the US. The facility manufactures a range of finished products, including oral solids and injectables. The US is the biggest market for the company, accounting for 43% of the total sales of Rs13,702 crore in 2015-16.

Be the first to comment

Leave a Reply

Your email address will not be published.